Rheumatology

Kyverna Therapeutics Congratulates Scientific Advisory Board Member Peter A. Merkel, M.D., M.P.H. on Receiving the 2023 ACR Distinguished Clinical Investigator Award

Retrieved on: 
Saturday, November 11, 2023
Medicine, Research, Epidemiology, Therapy, University, Scleroderma, Patient, CD19, American College of Rheumatology, American College, Rheumatology, Lupus nephritis, ACR, Vasculitis, Pharmaceutical industry

EMERYVILLE, Calif., Nov. 11, 2023 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, congratulates Peter A. Merkel, M.D., M.P.H., a member of the Kyverna's scientific advisory board, on receiving the 2023 ACR Distinguished Clinical Investigator Award by the American College of Rheumatology (ACR). The recognition is given annually to a member who exhibits outstanding contributions to the field of rheumatology.

Key Points: 
  • The recognition is given annually to a member who exhibits outstanding contributions to the field of rheumatology.
  • "All of us at Kyverna celebrate this well-deserved recognition of Dr. Merkel's impact in the field of rheumatology," said Peter Maag, Ph.D., chief executive officer of Kyverna.
  • Dr. Merkel's research focuses on clinical trial design and conduct, outcome-measure development, clinical epidemiology, genetic epidemiology, and biomarker discovery.
  • Dr. Merkel has been a Kyverna Advisory Board member since 2022.

Trevena to Release Third Quarter 2023 Financial Results on November 14, 2023

Retrieved on: 
Thursday, November 9, 2023
Rheumatology, SVP, Chronic pain, Psychiatry, CNS, University, Trevena, Webcast, Patient, Central nervous system, Pharmaceutical industry, Management, Medicine, Anesthesiology

CHESTERBROOK, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for the third quarter ended September 30, 2023, prior to the market open on Tuesday, November 14, 2023.

Key Points: 
  • CHESTERBROOK, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for the third quarter ended September 30, 2023, prior to the market open on Tuesday, November 14, 2023.
  • The Company will host a conference call and webcast with the investment community at 8:00 a.m.
  • ET that same day, featuring remarks by Carrie Bourdow, President and Chief Executive Officer, Mark Demitrack, M.D., SVP and Chief Medical Officer, and Barry Shin, SVP and Chief Financial Officer.
  • In addition, Dan Clauw, M.D., Professor of Anesthesiology, Medicine (Rheumatology) and Psychiatry at the University of Michigan and Director of the Chronic Pain and Fatigue Research Center will join the call as well.

Spherix Global Insights Amplifies the Lupus Patient Voice, Highlighting the Lengthy and Challenging Journey to Diagnosis and Treatment

Retrieved on: 
Wednesday, November 8, 2023
SLE, Steroid, Arthralgia, Patient, Lupus nephritis, Education, Social media, Rash, History, Human, Rheumatology, Prevalence, Skin, Rheumatoid arthritis, Kidney, Research, Migraine, Disease, Internet, Aurinia, Hypertension, Special, Stiffness, Joint, Swelling, Human voice, Irritation, Safety, Diagnosis, Fatigue, Nursing, Lupus

Upon consulting healthcare professionals, a substantial portion faced prolonged diagnostic journeys, enduring over a year to receive an accurate diagnosis.

Key Points: 
  • Upon consulting healthcare professionals, a substantial portion faced prolonged diagnostic journeys, enduring over a year to receive an accurate diagnosis.
  • Indeed, SLE patients commonly experience a myriad of concurrent health conditions, with approximately one-fifth officially diagnosed with lupus nephritis.
  • Notwithstanding this yearning for more information, the Lupus patient community remains remarkably self-empowered, often relying on personal research for insights into their condition.
  • Patient Voice Dynamix™ is an independent service that explores the voice of the patient as they progress through their disease and treatment journeys.

Global Healthy Living Foundation to Present Pioneering Patient-Centered Research at ACR Convergence 2023

Retrieved on: 
Thursday, November 9, 2023
Biometrics, Telemedicine, Virtual Medicine, Pharmaceutical, General Health, Health, Wearables, Mobile Technology, Technology, Other Health, Online, Rheumatism, American College, Hospital, Treatment, Face, Doctor of Philosophy, Medicine, Disease, Efficacy, COVID-19, Overalls, Culture, PRO, Pain, Medical Affairs Bureau, Gold, MPH, Impact, Additive effect, RA, American College of Rheumatology, Data management, Exercise, Patient, ACR, Plant, Rehabilitation, MD, Motivation, Mindfulness, Quality of life, Longitudinal study, Research, Osteoporosis, DSM-IV codes, Guideline, Rheumatoid arthritis, Role, TNF inhibitor, Pros, Conjoint analysis, Jaki, Poster, Ageing, WEAR, Pharmaceutical industry, Medical device, Medical imaging, Nursing, Dietary supplement, Diet, Rheumatology, Fatigue, Flare, Epidemiology, Arthritis

The Global Healthy Living Foundation and its digital, arthritis patient centered research registry, formerly ArthritisPower, will collaboratively present eight scientific abstracts and five patient perspective posters at the American College of Rheumatology Convergence 2023 (Philadelphia, PA, November 10-15, 2023).

Key Points: 
  • The Global Healthy Living Foundation and its digital, arthritis patient centered research registry, formerly ArthritisPower, will collaboratively present eight scientific abstracts and five patient perspective posters at the American College of Rheumatology Convergence 2023 (Philadelphia, PA, November 10-15, 2023).
  • Collectively, GHLF researchers will focus on innovative approaches to remote therapeutic monitoring, patient engagement, and personalized care in rheumatic and musculoskeletal diseases.
  • This study offers key insights on innovative disease tracking methods, including those that can happen outside traditional clinical settings, particularly for diseases like rheumatoid arthritis (RA).
  • GHLF anticipates engaging with fellow organizations and professionals at ACR Convergence to share their year-long accomplishments in rheumatic disease research.

TLC to Present Phase 3 Data of TLC599 in Late-Breaking Abstracts Session at ACR

Retrieved on: 
Wednesday, November 8, 2023
Week, ADP, University of Sydney, Chronic pain, WOMAC, University, Safety, Knee, Patient, ACR, TLC, Pharmaceutical industry, Rheumatology, Osteoarthritis

“The data from this pivotal Phase 3 trial demonstrates the sustained efficacy and safety of TLC599 out to 52 weeks.

Key Points: 
  • “The data from this pivotal Phase 3 trial demonstrates the sustained efficacy and safety of TLC599 out to 52 weeks.
  • On the average daily pain (ADP) scale, TLC599 was numerically and statistically superior to placebo at all time points during the first injection period.
  • Additionally, the reduction in ADP for TLC599 was statistically superior to the active comparator at Week 12.
  • TLC599 was generally well tolerated, with the number and type of adverse events similar among all three treatment groups.

ANI Pharmaceuticals Reports Record Third Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance

Retrieved on: 
Wednesday, November 8, 2023
Patient, FDA, Growth, ANI, Development, Rare disease, EBITDA, Nephrology, GAAP, ACTH, Anders, USP, Purified, CGT, Neurology, Generic, Rheumatology, Bank, Pharmaceutical industry, Video game, Generic drug, IQVIA

-- Generics, Established Brands and Other reported net sales of $102.1 million, representing year-over-year growth of 43.4% --

Key Points: 
  • Nikhil Lalwani, President and CEO of ANI stated, “Strong execution has resulted in another record quarter for revenue and adjusted non-GAAP EBITDA, positioning us to raise full year 2023 guidance for the third consecutive quarter.
  • Third Quarter 2023 Financial Highlights:
    Net revenues were $131.8 million compared to $83.8 million in Q3 2022.
  • Since the launch of Cortrophin Gel, the overall ACTH category has experienced six consecutive quarters of year-over-year growth from second quarter 2022 to third quarter 2023.
  • Sales of generic pharmaceuticals products, established brands and other grew 43.4% year-over-year in the third quarter of 2023.

AMGEN PRESENTS NEW RESEARCH IN EARLY PSORIATIC ARTHRITIS AT ACR 2023

Retrieved on: 
Tuesday, November 7, 2023
Patient, Rheumatology Research Foundation, Standard of care, Psoriasis, Headache, American College, VAS, Diarrhea, Research, Nausea, REM, MACR, Common, Amgen, University of Washington School of Medicine, Joint, University, AMGN, American College of Rheumatology, Nonsteroidal anti-inflammatory drug, Safety, LDA, Pain, ACR, BSA, Hospital, Body surface area, Disability, Psoriatic arthritis, Pharmaceutical industry, Medical imaging, Rheumatology

THOUSAND OAKS, Calif., Nov. 7, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from the global Phase 4 FOREMOST study evaluating Otezla® (apremilast) in patients with early oligoarticular psoriatic arthritis. FOREMOST is the first placebo-controlled study designed to specifically assess people with oligoarticular psoriatic arthritis with early disease duration of five or fewer years. Results will be presented at the American College of Rheumatology (ACR) Convergence 2023, Nov. 10-15 in San Diego.

Key Points: 
  • Placebo
    THOUSAND OAKS, Calif., Nov. 7, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from the global Phase 4 FOREMOST study evaluating Otezla® (apremilast) in patients with early oligoarticular psoriatic arthritis.
  • FOREMOST is the first placebo-controlled study designed to specifically assess people with oligoarticular psoriatic arthritis with early disease duration of five or fewer years.
  • Results will be presented at the American College of Rheumatology (ACR) Convergence 2023, Nov. 10-15 in San Diego.
  • "These patients experienced a significant reduction in psoriatic disease activity, a crucial finding for those in the early stages of the condition."

Revolo Biotherapeutics Presents New Data on ‘1805 at the American College of Rheumatology Convergence 2023 Annual Conference

Retrieved on: 
Tuesday, November 7, 2023
Rheumatology, American College, Conference, Inflammation, Cell, RA, San Diego Convention Center, University, Immune system, Gene, Clinical & Translational Immunology, Autoimmunity, Patient, Pharmaceutical industry, Vaccine

NEW ORLEANS and CAMBRIDGE, United Kingdom, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that new preclinical data on ‘1805 will be presented via two posters at the American College of Rheumatology Convergence 2023 Annual Conference, which is being held November 10–15 at the San Diego Convention Center in San Diego, CA.

Key Points: 
  • “These preclinical data provide further insights into ‘1805’s differentiated mechanism of action,” said Jonathan Rigby, Revolo’s Chief Executive Officer.
  • “While current RA treatments can in part ameliorate joint destruction, they are limited in the ability to prevent osteoclast-induced bone destruction.
  • In addition, ‘1805 normalizes the expression of genes abnormally activated in cells from RA patients, such as those associated with inflammation.
  • Altogether, the data support the clinical potential of ‘1805 and its further clinical evaluation.

Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with Lupus Nephritis at ACR 2023

Retrieved on: 
Tuesday, November 7, 2023
Biotechnology, Health, Science, Research, Clinical Trials, Patient, Lupus nephritis, Week, American College, CNI, EGFR, Human, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., TAC, AURORA, Safety, University of California, CSA, VCS, Lupus, Society, Mouse, Acute kidney injury, Ciclosporin, Division, Clinical trial, Efficacy, Physiology, Biopsy, MMF, University, Tacrolimus, Glucocorticoid, ACR, Conditional sentence, Proteinuria, Lithium toxicity, Pharmaceutical industry, Rheumatology, Black, ALMS, Aurinia, Medicine, UPCR, LN

Safety and efficacy outcomes for propensity-matched patients with active LN from the Aspreva Lupus Management Study (ALMS) and the AURORA 1 study were assessed at three and six months.

Key Points: 
  • Safety and efficacy outcomes for propensity-matched patients with active LN from the Aspreva Lupus Management Study (ALMS) and the AURORA 1 study were assessed at three and six months.
  • In AURORA 1, patients received LUPKYNIS® 23.7 mg BID in combination with MMF (target dose 2 g/day) and oral glucocorticoids (starting dose of 25 mg/day tapered to 2.5 mg/day by Week 16).
  • The data showed an improved safety profile over the first six months of treatment with LUPKYNIS® in combination with low-dose glucocorticoids and lower-dose MMF without compromising efficacy.
  • Additional data assessed the disposition of cyclosporine (CSA), tacrolimus (TAC), and voclosporin (VCS) in mouse kidneys relative to its systemic drug exposure.

Lupus Foundation of America Research Accomplishments to be Presented at the 2023 American College of Rheumatology Annual Meeting

Retrieved on: 
Tuesday, November 7, 2023
SLE, Rheumatology, Patient, Lupus Foundation of America, American College, RAY, Social media, Burden, CLE, Fatigue, Medicine, History, Racism, Language, Human, Observational study, Mental health, RN, Lupus, Doctor of Philosophy, News, MBBS, Social, HES, The Digital Intervention, Quality of life, Education, LFA, American Indians, Lead, Alaska Natives, Skin, Delphi, SELF, Communication, Monash University, Pharmaceutical industry, Nursing, Research, Diagnosis

WASHINGTON, Nov. 7, 2023 /PRNewswire/ -- The American College of Rheumatology Convergence 2023 meeting will be held in San Diego, CA from November 10-15, 2023.

Key Points: 
  • WASHINGTON, Nov. 7, 2023 /PRNewswire/ -- The American College of Rheumatology Convergence 2023 meeting will be held in San Diego, CA from November 10-15, 2023.
  • "As exploration and understanding of lupus grows, the Lupus Foundation of America continues to lead, contribute and support many novel and exciting investigations that propel the field forward," said Joy Buie, PhD, MSCR, RN, Director of Research, Lupus Foundation of America.
  • Throughout the ACR Meeting, the Lupus Foundation of America will share updates on social media highlighting the innovative scientific initiatives and research studies presented, as well as breaking news.
  • Follow the Lupus Foundation of America for evolving conference hot topics and research highlights at LFA's Twitter , Facebook , LinkedIn .